Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA

SC. Rutherford, M. Herold, W. Hiddemann, L. Kostakoglu, R. Marcus, M. Martelli, LH. Sehn, M. Trněný, J. Trotman, U. Vitolo, T. Nielsen, F. Mattiello, D. Sahin, G. Sellam, P. Martin

. 2020 ; 4 (8) : 1589-1593. [pub] 20200428

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020621

The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020621
003      
CZ-PrNML
005      
20210830102240.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2019001261 $2 doi
035    __
$a (PubMed)32298429
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rutherford, Sarah C $u Department of Medicine, Weill Cornell Medicine, New York, NY
245    10
$a Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA / $c SC. Rutherford, M. Herold, W. Hiddemann, L. Kostakoglu, R. Marcus, M. Martelli, LH. Sehn, M. Trněný, J. Trotman, U. Vitolo, T. Nielsen, F. Mattiello, D. Sahin, G. Sellam, P. Martin
520    9_
$a The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL.
650    _2
$a biopsie $7 D001706
650    12
$a kostní dřeň $7 D001853
650    _2
$a fluorodeoxyglukosa F18 $7 D019788
650    12
$a galium $7 D005708
650    _2
$a lidé $7 D006801
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Herold, Michael $u Helios Klinikum Erfurt, Erfurt, Germany
700    1_
$a Hiddemann, Wolfgang $u Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany
700    1_
$a Kostakoglu, Lale $u Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA
700    1_
$a Marcus, Robert $u King's College Hospital, London, United Kingdom
700    1_
$a Martelli, Maurizio $u Department of Translational and Precision Medicine, Hematology Section, "Sapienza" University, Rome, Italy
700    1_
$a Sehn, Laurie H $u BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada
700    1_
$a Trněný, Marek $u First Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Trotman, Judith $u Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
700    1_
$a Vitolo, Umberto $u Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Turin, Italy; and
700    1_
$a Nielsen, Tina $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Mattiello, Federico $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Sahin, Deniz $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Sellam, Gila $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Martin, Peter $u Department of Medicine, Weill Cornell Medicine, New York, NY
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 4, č. 8 (2020), s. 1589-1593
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32298429 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102241 $b ABA008
999    __
$a ok $b bmc $g 1691240 $s 1141067
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 4 $c 8 $d 1589-1593 $e 20200428 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace